Licensing status

Publication and contact information



Factor VIII

Mouse studies suggest phosphatidylserine-bound factor VIII could help treat patients with hemophilia A. Patients with hemophilia A lack factor VIII and often develop an antibody response against factor VIII replacement therapy that limits therapeutic benefit. In a mouse model for hemophilia A, pretreatment with factor VIII linked to phosphatidylserine (FVIII-PS) led to a decreased anti-factor VIII antibody response compared with pretreatment using free factor VIII. Next steps include optimizing the FVIII-PS dosage and conducting clinical tests.
At least nine companies have factor VIII-based compounds in development stages ranging from Phase II trials to market for treating hemophilia.

SciBX 6(22); doi:10.1038/scibx.2013.548
Published online June 6, 2013

Patent application filed; available for licensing

Gaitonde, P. et al. J. Biol. Chem.; published online May 6, 2013;
Contact: Sathy V. Balu-Iyer, University at Buffalo, Buffalo, N.Y.